Dear SITS User

Newsletter June 2020

With this newsletter we would like to inform you about SITS activities

Launching COVID-19 stroke specific variables

Upon request from the SITS users, we are launching COVID-19 stroke specific variables in the registry. The new variables will help you to gather local knowledge, practice and outcomes in stroke treatment related to patients who are suspected or confirmed with COVID-19.

As Local Coordinator and Local User, when you log in, a pop-up window will appear asking you whether you want to enable the COVID-19 stroke specific variables or not. If you select “Yes”, the variables will be activated in your centre for the following protocols:

- IVT (standard and minimal)
- IVT+TBY Bridge
- TBY
- APP (standard and minimal)

Once the variables have been enabled in your centre, they are located at one separate subject page. You can enter the page via the “Patient Summary” page, as entering any other time point.

SITS IVT Paediatrics Study

Until recently, Intravenous thrombolysis (IVT) with alteplase was not approved in patients with acute ischaemic stroke aged under 18 years. Based on observational data, regulatory authorities in several countries have now approved use of IVT with alteplase in patients 16-18 years if other Summary of Product Criteria (SmPC) are fulfilled. Regulatory authorities have requested monitoring of treatment in this age group, SITS is therefore collecting data of IVT in patients with acute ischaemic stroke aged 16-18 years. The Swedish ethics committee has recently approved collection of data for this age group. We encourage all SITS centres to enter data in the SITS IVT registry. Interested centres can inform their paediatrics department about the upcoming study.

Please contact us at info@sitsinternational.org for more information.
SITS Elderly IVT> 80 years study

Intravenous thrombolysis (IVT) with alteplase in acute ischaemic stroke > 80 years old is approved in several European and non-European countries since July 2018. Although IVT in patients >80 years has been used off-label in many countries prior to approval, use of IVT in patients>80 years will probably be more frequent after approval. European authorities have requested monitoring of IVT>80 years in acute ischaemic stroke. Centres with high quality and complete data recording in the SITS International Thrombolysis Registry will be invited to join the study when sufficient data is collected.

As always, thank you for your collaboration. We are sending you our best thoughts and regards.

Be safe and stay well.

Best regards
SITS Coordination Team